Published: 21. August, 2025
The Company has advanced well with its planned activities Positive and clinical meaningful top-line…
The Company has advanced well with its planned activities
Positive and clinical meaningful top-line results from Study 0202
New US manufacturing technology transfer nearing completion
CT001 dossier development for EMA submission; filled and validated 14. August
Organisational development, promotion of M. Juhl to Executive Management
Strengthening the financial position with a direct issue of DKK 14.6 mill
Comments from CEO, Jes Trygved:
Recent highlights include significant operational and regulatory advancements, with the US manufacturing tech-transfer nearing completion and the CT001 dossier actively being developed for EMA submission. To support this growth, the organisation has been strengthened through the promotion of Martin Juhl to the Executive Management team, and our financial position has been fortified by a recent directed issue of DKK 14.6 million. The positive top-line results from Study 0202 represent a critical milestone, forming a key component of our regulatory submissions and future partner commercial activities. Thanks for a great effort by the team!
Link to Report: Q2-2025 Report
